Literature DB >> 12057128

Ovarian tumors of low malignant potential.

E L Trimble1, C L Trimble.   

Abstract

Ovarian tumors of low malignant potential (LMP) differ from epithelial ovarian carcinoma in etiology, molecular biology, and prognosis. LMP tumors are not precursor lesions to ovarian carcinoma. Treatment is primarily surgical. Women found to have an ovarian tumor of LMP should undergo removal of the involved adnexa; surgical staging; and cytoreductive surgery. Women in the reproductive years should be given the option of conservative surgery, preserving the contralateral adnexa and uterus. There is no proven benefit to adjuvant chemotherapy or radiotherapy after primary surgery. In most cases, the diagnosis of an ovarian tumor of LMP conveys good prognosis, with excellent long-term survival.

Entities:  

Mesh:

Year:  2001        PMID: 12057128     DOI: 10.1007/s11864-001-0052-2

Source DB:  PubMed          Journal:  Curr Treat Options Oncol        ISSN: 1534-6277


  32 in total

1.  Prognostic significance of p53 expression in advanced-stage ovarian serous borderline tumors.

Authors:  D M Gershenson; M Deavers; S Diaz; G Tortolero-Luna; B E Miller; R C Bast; G B Mills; E G Silva
Journal:  Clin Cancer Res       Date:  1999-12       Impact factor: 12.531

2.  Evaluation of diagnostic criteria and behavior of ovarian intestinal-type mucinous tumors: atypical proliferative (borderline) tumors and intraepithelial, microinvasive, invasive, and metastatic carcinomas.

Authors:  M A Riopel; B M Ronnett; R J Kurman
Journal:  Am J Surg Pathol       Date:  1999-06       Impact factor: 6.394

3.  Prognosis of patients with ovarian cancer and borderline tumours diagnosed in Norway between 1954 and 1993.

Authors:  T Bjørge; A Engeland; S Hansen; C G Tropé
Journal:  Int J Cancer       Date:  1998-03-02       Impact factor: 7.396

4.  Outcome and reproductive function after conservative surgery for borderline ovarian tumors.

Authors:  R T Morris; D M Gershenson; E G Silva; M Follen; M Morris; J T Wharton
Journal:  Obstet Gynecol       Date:  2000-04       Impact factor: 7.661

5.  Comparison of mutations of Ki-RAS and p53 immunoreactivity in borderline and malignant epithelial ovarian tumors.

Authors:  R F Caduff; S M Svoboda-Newman; A W Ferguson; C M Johnston; T S Frank
Journal:  Am J Surg Pathol       Date:  1999-03       Impact factor: 6.394

6.  Ovarian serous borderline tumors with invasive peritoneal implants.

Authors:  D M Gershenson; E G Silva; L Levy; T W Burke; J K Wolf; C Tornos
Journal:  Cancer       Date:  1998-03-15       Impact factor: 6.860

7.  Serous borderline tumors of the ovary with noninvasive peritoneal implants.

Authors:  D M Gershenson; E G Silva; G Tortolero-Luna; C Levenback; M Morris; C Tornos
Journal:  Cancer       Date:  1998-11-15       Impact factor: 6.860

8.  Evidence for the multifocal origin of bilateral and advanced human serous borderline ovarian tumors.

Authors:  K H Lu; D A Bell; W R Welch; R S Berkowitz; S C Mok
Journal:  Cancer Res       Date:  1998-06-01       Impact factor: 12.701

9.  Platinum-based chemotherapy for advanced-stage serous ovarian carcinoma of low malignant potential.

Authors:  R R Barakat; I Benjamin; J L Lewis; P E Saigo; J P Curtin; W J Hoskins
Journal:  Gynecol Oncol       Date:  1995-12       Impact factor: 5.482

10.  Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. III. Epithelial tumors of low malignant potential in white women. Collaborative Ovarian Cancer Group.

Authors:  R Harris; A S Whittemore; J Itnyre
Journal:  Am J Epidemiol       Date:  1992-11-15       Impact factor: 4.897

View more
  2 in total

1.  Mutation of ERBB2 provides a novel alternative mechanism for the ubiquitous activation of RAS-MAPK in ovarian serous low malignant potential tumors.

Authors:  Michael S Anglesio; Jeremy M Arnold; Joshy George; Anna V Tinker; Richard Tothill; Nic Waddell; Lisa Simms; Bianca Locandro; Sian Fereday; Nadia Traficante; Peter Russell; Raghwa Sharma; Michael J Birrer; Anna deFazio; Georgia Chenevix-Trench; David D L Bowtell
Journal:  Mol Cancer Res       Date:  2008-11       Impact factor: 5.852

2.  CPH-I and HE4 Are More Favorable Than CA125 in Differentiating Borderline Ovarian Tumors from Epithelial Ovarian Cancer at Early Stages.

Authors:  Zhiheng Wang; Xiang Tao; Chunmei Ying
Journal:  Dis Markers       Date:  2019-10-13       Impact factor: 3.434

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.